- Interim results from Phase 2 innovaTV 207 trial of tisotumab vedotin in head and neck cancer to be presented Initial Phase 1 dose-escalation data for SEA-TGT monotherapy in advanced malignancies to be disclosed Preclinical data and discovery research underscore Seagen’s mission to innovate through next-gener.